High dose chemotherapy in light chain or light and heavy chain deposition disease

Kidney International

Volumn 65, Issue 2, 2004, Pages 642-648

  Royer, Bruno ^b   Arnulf, Bertrand ^b   Martinez, Frank ^b   Roy, Lydia ^b   Flageul, Béatrice ^b   Etienne, Isabelle ^b   Ronco, Pierre ^b   Brouet, Jean Claude ^b   Fermand, Jean Paul ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

Autologous stem cell transplantation; High dose therapy; Light (and or heavy) chain deposition disease

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; APLASIA; ARTICLE; AUTOTRANSPLANTATION; BACTERIAL INFECTION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; COMA; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART MUSCLE BIOPSY; HEAVY CHAIN DISEASE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN LIGHT CHAIN DISEASE; KIDNEY DISEASE; LIVER BIOPSY; LIVER DISEASE; MALE; MEDICAL EXAMINATION; MULTIPLE MYELOMA; NEUROTOXICITY; PARAPROTEINEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REMISSION; SEPSIS; SKIN BIOPSY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 1642561684     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00427.x     Document Type: Article

References (21)

1. BUXBAUM J, GALLO G: Non amyloidotic monoclonal immunoglobulin deposition disease. Hematol Oncol Clin North Am 13:1235-1248, 1999
2. RANDALL RE, WILLIAMSON WC JR, MULLINAX F, et al: Manifestations of systemic light chain deposition. Am J Med 60:293-299, 1976
3. RONCO PM, AUCOUTURIER P, MOUGENOT B: Monoclonal gammopathies: multiple myeloma, amyloidosis, and related disorders, in Diseases of the Kidney, 7th edition, edited by Schrier RW, Philadelphia, Lippincott, William and Wilkins, 2001 (in press)
4. DHODAPKAR MV, MERLINI G, SOLOMON A: Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am 11:89-110, 1997
5. SELBY P, MC ELWAIN TJ, NANDI AC, et al: Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55-62, 1987
6. BALLESTER OF, TUMMALA R, JANSSEN WE, et al: High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 20:653-656, 1997
7. SAN MIGUEL JF, LAHUERTA JJ, GARCIA-SANZ R, et al: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 1:28-36, 2000
8. MARIETTE X, CLAUVEL JP, BROUET JC: Intensive therapy in AL amyloidosis and light-chain deposition disease. Ann Intern Med 123:553, 1995
9. DURIE BG, SALMON SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854, 1975
10. FERMAND JP, RAVAUD P, CHEVRET S, et al: High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998
11. GERTZ MA, LACY MQ, GASTINEAU DA, et al: Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26:963-969, 2000
12. REITER E, KALHS P, KEIL F, et al: Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol 78:189-191, 1999
13. BADROS A, BARLOGIE B, SIEGEL E, et al: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Brit J Haematol 114:822-829, 2001
14. CASSERLY LF, FADIA A, SANCHORAWALA V, et al: High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis- associated end-stage renal disease. Kidney Int 63:1051-1057, 2003
15. GANEVAL D, MIGNON F, PREUD'HOMME JL, et al: Visceral deposition of monoclonal light chains and immunoglobulins: a study of renal and immunopathologic abnormalities. Adv Nephrol Necker Hospital 11:25-63, 1982
16. SCHUH A, DANDRIDGE J, HAYDON P, LITTLEWOOD TJ: Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant 24:1141-1143, 1999
17. TRICOT G, ALBERTS DS, JOHNSON C, et al: Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 2:947-952, 1996
18. POZZI C, FOGAZZI GB, BANFI G, et al: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 43:281-287; 1995
19. HEILMAN RL, VELOSA JA, HOLLEY KE, et al: Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20:34-41, 1992
20. MOREAU P, LEBLOND V, BOURQUELOT P, et al: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 101:766-769, 1998
21. COMENZO RL, VOSBURGH E, FALK RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670, 1998